๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II study of intravenous melphalan (NSC-8806) in the treatment of patients with advanced squamous carcinoma of the head and neck

โœ Scribed by Merrill S. Kies; David Grinblatt; Melissa Runge-Morris; Richard Blough; Arletrice Watkins; Sam Taylor

Publisher
Springer US
Year
1994
Tongue
English
Weight
242 KB
Volume
12
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II study of mitoxantrone in advanc
Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck
โœ Stephen D. Williams; Robert Birch; Enrique Velez-Garcia; Richard Gams ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› Springer US ๐ŸŒ English โš– 170 KB

A phase II study of mitoxantrone in squamous cell carcinoma of head and neck origin was conducted. Fiftythree evaluable patients were treated with this agent at a dosage of 5 mg/M2/week. The majority of patients were of high performance status. Twenty-seven patients had received previous chemotherap

A phase II study of piritrexim in patien
A phase II study of piritrexim in patients with advanced squamous head and neck cancer
โœ Wu-Ching Uen; Andrew T. Huang; Robert Mennel; Stephen E. Jones; Monica B. Spauld ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 347 KB ๐Ÿ‘ 3 views

Piritrexim (PTX) is a newly developed lipid-soluble folate antagonist that crosses the cell membrane by a simple, rapid, carrier-independent diffusion process. A Phase II study was conducted to evaluate the activity of PTX in 34 patients with previously chemotherapy-naive squamous cell cancer of the